Efficacy of hemocontrol biofeedback system in intradialytic hypotension-prone hemodialysis patients

Hyo Wook Gil, Kitae Bang, So Young Lee, Byoung Geun Han, Jin Kuk Kim, Young Ok Kim, Ho Cheol Song, Young-Joo Kwon, Yong Soo Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We conducted a study to determine whether the hemocontrol biofeedback system (HBS) can improve intradialytic hypotension (IDH) in hypotension-prone hemodialysis (HD) patients compared with conventional HD. In this multicenter prospective crossover study, 60 hypotension-prone patients were serially treated by conventional HD for 8 weeks (period A), by HD with hemoscan blood volume monitoring for 2 weeks (period B0), and by HBS HD for 8 weeks (period B1). The number of sessions complicated by symptomatic IDH during 24 HD sessions (14.9±5.8 sessions, 62.1% in period A vs 9.2±7.2 sessions, 38.4% in period B1, P<0.001) and the number of IDH-related nursing interventions in a session (0.96±0.66 in period A vs 0.56±0.54 in period B1, P<0.001) significantly decreased in period B1 than in period A. Recovery time from fatigue after dialysis was significantly shorter in period B1 than in period A. The patients with higher post-dialysis blood pressure, lower difference between pre-and post-dialysis blood pressure, less frequent IDH, and higher pre-and post-dialysis body weight in period A responded better to HBS in period B1 in regard to the reduction of IDH. In conclusion, HBS may improve the patient tolerability to HD by reducing the IDH frequency and promoting faster recovery from fatigue after dialysis.

Original languageEnglish
Pages (from-to)805-810
Number of pages6
JournalJournal of Korean Medical Science
Volume29
Issue number6
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Hypotension
Renal Dialysis
Dialysis
Fatigue
Blood Pressure
Blood Volume
Cross-Over Studies
Nursing
Body Weight
Prospective Studies

Keywords

  • Clinical trial
  • Dialysis volume
  • Hypotension
  • Renal dialysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of hemocontrol biofeedback system in intradialytic hypotension-prone hemodialysis patients. / Gil, Hyo Wook; Bang, Kitae; Lee, So Young; Han, Byoung Geun; Kim, Jin Kuk; Kim, Young Ok; Song, Ho Cheol; Kwon, Young-Joo; Kim, Yong Soo.

In: Journal of Korean Medical Science, Vol. 29, No. 6, 01.01.2014, p. 805-810.

Research output: Contribution to journalArticle

Gil, Hyo Wook ; Bang, Kitae ; Lee, So Young ; Han, Byoung Geun ; Kim, Jin Kuk ; Kim, Young Ok ; Song, Ho Cheol ; Kwon, Young-Joo ; Kim, Yong Soo. / Efficacy of hemocontrol biofeedback system in intradialytic hypotension-prone hemodialysis patients. In: Journal of Korean Medical Science. 2014 ; Vol. 29, No. 6. pp. 805-810.
@article{0e4a82e9036a4e4980a04b9f9c3d6310,
title = "Efficacy of hemocontrol biofeedback system in intradialytic hypotension-prone hemodialysis patients",
abstract = "We conducted a study to determine whether the hemocontrol biofeedback system (HBS) can improve intradialytic hypotension (IDH) in hypotension-prone hemodialysis (HD) patients compared with conventional HD. In this multicenter prospective crossover study, 60 hypotension-prone patients were serially treated by conventional HD for 8 weeks (period A), by HD with hemoscan blood volume monitoring for 2 weeks (period B0), and by HBS HD for 8 weeks (period B1). The number of sessions complicated by symptomatic IDH during 24 HD sessions (14.9±5.8 sessions, 62.1{\%} in period A vs 9.2±7.2 sessions, 38.4{\%} in period B1, P<0.001) and the number of IDH-related nursing interventions in a session (0.96±0.66 in period A vs 0.56±0.54 in period B1, P<0.001) significantly decreased in period B1 than in period A. Recovery time from fatigue after dialysis was significantly shorter in period B1 than in period A. The patients with higher post-dialysis blood pressure, lower difference between pre-and post-dialysis blood pressure, less frequent IDH, and higher pre-and post-dialysis body weight in period A responded better to HBS in period B1 in regard to the reduction of IDH. In conclusion, HBS may improve the patient tolerability to HD by reducing the IDH frequency and promoting faster recovery from fatigue after dialysis.",
keywords = "Clinical trial, Dialysis volume, Hypotension, Renal dialysis",
author = "Gil, {Hyo Wook} and Kitae Bang and Lee, {So Young} and Han, {Byoung Geun} and Kim, {Jin Kuk} and Kim, {Young Ok} and Song, {Ho Cheol} and Young-Joo Kwon and Kim, {Yong Soo}",
year = "2014",
month = "1",
day = "1",
doi = "10.3346/jkms.2014.29.6.805",
language = "English",
volume = "29",
pages = "805--810",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "6",

}

TY - JOUR

T1 - Efficacy of hemocontrol biofeedback system in intradialytic hypotension-prone hemodialysis patients

AU - Gil, Hyo Wook

AU - Bang, Kitae

AU - Lee, So Young

AU - Han, Byoung Geun

AU - Kim, Jin Kuk

AU - Kim, Young Ok

AU - Song, Ho Cheol

AU - Kwon, Young-Joo

AU - Kim, Yong Soo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We conducted a study to determine whether the hemocontrol biofeedback system (HBS) can improve intradialytic hypotension (IDH) in hypotension-prone hemodialysis (HD) patients compared with conventional HD. In this multicenter prospective crossover study, 60 hypotension-prone patients were serially treated by conventional HD for 8 weeks (period A), by HD with hemoscan blood volume monitoring for 2 weeks (period B0), and by HBS HD for 8 weeks (period B1). The number of sessions complicated by symptomatic IDH during 24 HD sessions (14.9±5.8 sessions, 62.1% in period A vs 9.2±7.2 sessions, 38.4% in period B1, P<0.001) and the number of IDH-related nursing interventions in a session (0.96±0.66 in period A vs 0.56±0.54 in period B1, P<0.001) significantly decreased in period B1 than in period A. Recovery time from fatigue after dialysis was significantly shorter in period B1 than in period A. The patients with higher post-dialysis blood pressure, lower difference between pre-and post-dialysis blood pressure, less frequent IDH, and higher pre-and post-dialysis body weight in period A responded better to HBS in period B1 in regard to the reduction of IDH. In conclusion, HBS may improve the patient tolerability to HD by reducing the IDH frequency and promoting faster recovery from fatigue after dialysis.

AB - We conducted a study to determine whether the hemocontrol biofeedback system (HBS) can improve intradialytic hypotension (IDH) in hypotension-prone hemodialysis (HD) patients compared with conventional HD. In this multicenter prospective crossover study, 60 hypotension-prone patients were serially treated by conventional HD for 8 weeks (period A), by HD with hemoscan blood volume monitoring for 2 weeks (period B0), and by HBS HD for 8 weeks (period B1). The number of sessions complicated by symptomatic IDH during 24 HD sessions (14.9±5.8 sessions, 62.1% in period A vs 9.2±7.2 sessions, 38.4% in period B1, P<0.001) and the number of IDH-related nursing interventions in a session (0.96±0.66 in period A vs 0.56±0.54 in period B1, P<0.001) significantly decreased in period B1 than in period A. Recovery time from fatigue after dialysis was significantly shorter in period B1 than in period A. The patients with higher post-dialysis blood pressure, lower difference between pre-and post-dialysis blood pressure, less frequent IDH, and higher pre-and post-dialysis body weight in period A responded better to HBS in period B1 in regard to the reduction of IDH. In conclusion, HBS may improve the patient tolerability to HD by reducing the IDH frequency and promoting faster recovery from fatigue after dialysis.

KW - Clinical trial

KW - Dialysis volume

KW - Hypotension

KW - Renal dialysis

UR - http://www.scopus.com/inward/record.url?scp=84925226276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925226276&partnerID=8YFLogxK

U2 - 10.3346/jkms.2014.29.6.805

DO - 10.3346/jkms.2014.29.6.805

M3 - Article

VL - 29

SP - 805

EP - 810

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 6

ER -